Navigation Links
Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its 'Tai' Drug Series
Date:6/18/2009

NANTONG CITY, China, June 18 /PRNewswire/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce today that it has received approval and authentication from the Trademark Bureau of China for its pre-surgical skeletal muscle relaxant Cisatracurium Besylate, marketed as Kutai, and its newly launched formulation of the anti-hypertension drug Perindopril, marketed as Yitai.

Kutai has gained rapid market acceptance and is building strong brand loyalty in China. Within 14 months of its launch there in late 2006, it has captured 80 percent of the Chinese market and is now in use in more than 700 hospitals across the country.

As the first Chinese produced Perindopril, Sinobiopharma's Yitai is a first-to-market (FTM) drug with significant competitive advantages. They include a higher price point that the Chinese government sets for FTM drugs and exclusivity for hospital contracts. Sinobiopharma's technology enables the production of a Perindopril formulation with lower cost active pharmaceutical ingredients (API), a high quality tablet and greater efficacy and reduced side effects compared to earlier versions of the drug. The technology also affords the potential for developing the world's first capsule formulation, which would make for easier swallowing.

The English name for the "Tai" trademark was taken from the Mandarin for "healthy". The name reflects Sinobiopharma's focus on health through the development of innovative, affordable therapies.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
2. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
3. Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008
4. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
5. DaVita Receives Civil Complaint
6. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
7. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
8. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
11. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 21, 2017 , ... "ProDOF is the perfect set of tools for video editors that want ... scene," said Christina Austin - CEO of Pixel Film Studios. , Video editors using ... illusion of a DSLR racking focus from one area into the next. ProDOF comes ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, ... experience the freedom of recovery, they often feel shame for having struggled with an ... disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- ...
(Date:1/20/2017)... , ... January 20, 2017 , ... A new partnership ... items they no longer use or need, from clothes to couches to dressers and ... items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology: